Daniel Booser
Overview
Explore the profile of Daniel Booser including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
1342
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sinn B, Fu C, Lau R, Litton J, Tsai T, Murthy R, et al.
NPJ Breast Cancer
. 2019 Jun;
5:16.
PMID: 31231679
There is a clinical need to predict sensitivity of metastatic hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer to endocrine therapy, and targeted RNA sequencing (RNAseq) offers diagnostic potential to measure...
2.
Murthy R, Varma A, Mishra P, Hess K, Young E, Murray J, et al.
Cancer
. 2014 Mar;
120(13):1932-8.
PMID: 24677057
Background: The purpose of the current study was to describe the outcomes of patients with human epidermal growth factor receptor 2 (HER2)-overexpressed/amplified (HER2+) early breast cancer who received adjuvant or...
3.
Dean-Colomb W, Hess K, Young E, Gornet T, Handy B, Moulder S, et al.
Breast Cancer Res Treat
. 2012 Dec;
137(2):631-6.
PMID: 23242617
Bone is the most common site of metastasis of breast cancer, affecting most women with advanced disease. Procollagen type I N-terminal propeptide (P1NP), osteocalcin, CTX, and IL-6 are markers of...
4.
Iwamoto T, Booser D, Valero V, Murray J, Koenig K, Esteva F, et al.
J Clin Oncol
. 2012 Feb;
30(7):729-34.
PMID: 22291085
Purpose: We examined borderline estrogen receptor (ER) -positive cancers, defined as having 1% to 10% positivity by immunohistochemistry (IHC), to determine whether they show the same global gene-expression pattern and...
5.
Arun B, Dhinghra K, Valero V, Kau S, Broglio K, Booser D, et al.
Oncologist
. 2011 Nov;
16(11):1527-34.
PMID: 22042783
Objective: To compare the pathologic complete response (pCR) rate of patients treated with 5-fluorouracil (5-FU), doxorubicin, and cyclophosphamide (FAC) versus dose-intense FAC plus G-CSF in the neoadjuvant setting and to...
6.
Moulder S, Gladish G, Ensor J, Gonzalez-Angulo A, Cristofanilli M, Murray J, et al.
Cancer
. 2011 Oct;
118(9):2378-84.
PMID: 22006179
Background: Inhibition of mammalian target of rapamycin with everolimus may improve the efficacy of taxanes. Everolimus and docetaxel are both metabolized by CYP3A4, which could result in a pharmacokinetic (PK)...
7.
Moulder S, Moroney J, Helgason T, Wheler J, Booser D, Albarracin C, et al.
J Clin Oncol
. 2011 Apr;
29(19):e572-5.
PMID: 21482991
No abstract available.
8.
Iwamoto T, Bianchini G, Booser D, Qi Y, Coutant C, Shiang C, et al.
J Natl Cancer Inst
. 2010 Dec;
103(3):264-72.
PMID: 21191116
Background: We hypothesized that distinct biological processes might be associated with prognosis and chemotherapy sensitivity in the different types of breast cancers. Methods: We performed gene set analyses with BRB-ArrayTools...
9.
Popovici V, Chen W, Gallas B, Hatzis C, Shi W, Samuelson F, et al.
Breast Cancer Res
. 2010 Jan;
12(1):R5.
PMID: 20064235
Introduction: As part of the MicroArray Quality Control (MAQC)-II project, this analysis examines how the choice of univariate feature-selection methods and classification algorithms may influence the performance of genomic predictors...
10.
Ueno N, de Souza J, Booser D, Nakayama K, Madewell J, Wendt 3rd R, et al.
Clin Breast Cancer
. 2009 Aug;
9(3):173-7.
PMID: 19661041
Purpose: Bone-targeted radiation therapy is an attractive strategy for addressing bone disease with minimal systemic toxicity. This pilot study was designed to determine the safety and efficacy of (166)Holmium (Ho)-DOTMP...